NCT07684508 Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer
| NCT ID | NCT07684508 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Manni Huang |
| Condition | Hypofractionated Radiotherapy |
| Study Type | INTERVENTIONAL |
| Enrollment | 154 participants |
| Start Date | 2026-07-10 |
| Primary Completion | 2030-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 154 participants in total. It began in 2026-07-10 with a primary completion date of 2030-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancer
Eligibility Criteria
Inclusion Criteria: * ECOG performance status 0 or 1; * Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; * Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months; * For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the "four-factor model"; * Bone marrow function: white blood cell (WBC) count ≥3.0×10⁹/L, neutrophil count (NEUT) ≥1.5×10⁹/L, platelet count (PLT) ≥80×10⁹/L, hemoglobin (Hb) ≥90 g/L; renal function: normal or serum creatinine (SCr) ≤1.5×upper limit of normal (ULN) or creatinine clearance ≥50 ml/min; hepatic function: total bilirubin (TBIL) ≤1.5×ULN, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5×ULN; * Voluntarily signed the informed consent form prior to study enrollment. Exclusion Criteria: * History of active malignant tumor within 3 years prior to initial treatment（except for the cervical cancer）and any locally curable tumors treated with radical therapy; * Any high-risk factor confirmed by postoperative pathology: positive lymph node metastasis, positive parametrial invasion, or positive resection margin; * History of neoadjuvant therapy prior to enrollment; * Local recurrence or distant metastasis prior to enrollment; * Postoperative intestinal obstruction or intestinal adhesion; * Severe cardiac, cerebral, hepatic, or renal disorders; * Long-term immunocompromised state; * Pregnant or lactating females; * Premature discontinuation of treatment for any reason; * Poor compliance, unwillingness to participate, or inability to cooperate with follow-up; * Any other conditions deemed unsuitable for this trial by the investigator.
Contact & Investigator
MAN NI HUANG, MD
PRINCIPAL INVESTIGATOR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Frequently Asked Questions
Who can join the NCT07684508 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 75 Years, studying Hypofractionated Radiotherapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07684508 currently recruiting?
Yes, NCT07684508 is actively recruiting participants. Contact the research team at huangmanni@csco.ac.cn for enrollment information.
Where is the NCT07684508 trial being conducted?
This trial is being conducted at Beijing, China, Langfang, China.
Who is sponsoring the NCT07684508 clinical trial?
NCT07684508 is sponsored by Manni Huang. The principal investigator is MAN NI HUANG, MD at Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 154 participants.